1-4 of 4
John R. Eckardt, MD
Close
Sort by
Journal Articles

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Hiroto Inaba, MD PhD, John C Panetta, PhD, Daelynn R Buelow, PhD, Raul C. Ribeiro, MD, John R. Eckardt, MD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 3937.
https://doi.org/10.1182/blood.V128.22.3937.3937
Published: 2016
Journal Articles

Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Elias J. Jabbour, MD, Naval Daver, MD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Jan A. Burger, MD PhD, Kiran Naqvi, MD, Christopher B. Benton, MD, Prithviraj Bose, MD, John R. Eckardt, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2016) 128 (22): 2744.
https://doi.org/10.1182/blood.V128.22.2744.2744
Published: 2016
Journal Articles

Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML

Swaminathan P. Iyer, MD, Yogesh Jethava, MD, Chatchada Karanes, MD, John R. Eckardt, MD, Robert Collins
Journal: Blood
Blood (2016) 128 (22): 3983.
https://doi.org/10.1182/blood.V128.22.3983.3983
Published: 2016
Journal Articles

Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)

Eunice S. Wang, MD, Richard M. Stone, MD, Martin S. Tallman, MD, Roland B. Walter, MD PhD, John R. Eckardt, MD, Robert Collins
Journal: Blood
Blood (2016) 128 (22): 1071.
https://doi.org/10.1182/blood.V128.22.1071.1071
Published: 2016